NASDAQ · NGNE
Neurogene Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NGNE: Nov 12, 2026
Neurogene Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.49. The reported EPS for the same quarter last year was $-0.99.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.49 | $-1.36 | $-1.69 | 5 |
| Dec 2026 | $-1.47 | $-1.20 | $-1.64 | 5 |
| Mar 2027 | $-1.48 | $-1.22 | $-1.73 | 2 |
| Jun 2027 | $-1.59 | $-1.24 | $-1.93 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews- Zacks · Oct 13, 9:01 AM EDTCan Nuplazid and Daybue Strengthen Acadia's Growth Prospects?ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
- Fintel · Oct 8, 4:51 PM EDTJP Morgan Initiates Coverage of Neurogene at OverweightFintel reports that on October 8, 2026, JP Morgan initiated coverage of Neurogene (NASDAQGM:NGNE) (DB:UU8) with a Overweight recommendation.Prior to this rating action, the stock closed at $25.87 on October 7, 2026. This latest close represents a price change of -7.01% over one w
- RTTNews · Aug 14, 10:53 AM EDTNeurogene Reports Wider Q2 Loss; Anticipates Embolden Trial Data In H2 2027(RTTNews) – Neurogene Inc. (NGNE) reported second quarter results showing a wider loss due to higher operating expenses, mainly associated with Research and Development costs.
- RTTNews · Jun 29, 8:52 AM EDTNeurogene Reports Positive Long-Term Phase 1/2 Data For Rett Syndrome Gene Therapy(RTTNews) – Neurogene Inc. (NGNE) on Monday reported positive long-term data from its Phase 1/2 study of NGN-401 in females with Rett syndrome, a rare neurological disorder that primarily affects girls.
- Fintel · Mar 27, 9:49 AM EDTNeurogene (NGNE) Price Target Increased by 37.29% to 82.62The average one-year price target for Neurogene (NasdaqGM:NGNE) has been revised to $82.62 / share. This is an increase of 37.29% from the prior estimate of $60.18 dated February 21, 2026. The price target is an average of many targets provided by analysts. Th
- Fintel · Feb 27, 3:03 PM ESTCanaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy RecommendationFintel reports that on February 27, 2026, Canaccord Genuity initiated coverage of Neurogene (NasdaqGM:NGNE) with a Buy recommendation. Analyst Price Forecast Suggests 205.79% Upside
- RTTNews · Feb 26, 7:56 PM ESTNeurogene Gets FDA Breakthrough Tag For NGN-401 In Rett Syndrome; Stock Up(RTTNews) – Neurogene Inc. (NGNE) announced that the U.S. FDA has granted Breakthrough Therapy designation to NGN-401, its investigational gene therapy for Rett syndrome.
- Fintel · Jan 26, 7:03 PM ESTLifeSci Capital Initiates Coverage of Neurogene (NGNE) with Outperform RecommendationFintel reports that on January 26, 2026, LifeSci Capital initiated coverage of Neurogene (NasdaqGM:NGNE) with a Outperform recommendation. Analyst Price Forecast Suggests 213.93% Upside
- RTTNews · Jan 11, 10:55 PM ESTAfter-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers(RTTNews) – Several biotech and healthcare names posted notable gains in after-hours trading on Friday, with investors showing renewed interest in companies tied to drug development, healthcare services, and financing updates.
- Fintel · Nov 17, 4:59 PM ESTNeurogene (NGNE) Price Target Increased by 11.85% to 60.18The average one-year price target for Neurogene (NasdaqGM:NGNE) has been revised to $60.18 / share. This is an increase of 11.85% from the prior estimate of $53.80 dated November 7, 2025. The price target is an average of many targets provided by analysts. The
- Fintel · Nov 13, 2:53 PM ESTHC Wainwright & Co. Maintains Neurogene (NGNE) Buy RecommendationFintel reports that on November 13, 2025, HC Wainwright & Co. maintained coverage of Neurogene (NasdaqGM:NGNE) with a Buy recommendation. Analyst Price Forecast Suggests 73.12% Upside
- Fintel · Oct 29, 8:10 AM EDTNeurogene (NGNE) Price Target Increased by 11.29% to 53.80The average one-year price target for Neurogene (NasdaqGM:NGNE) has been revised to $53.80 / share. This is an increase of 11.29% from the prior estimate of $48.35 dated September 27, 2025. The price target is an average of many targets provided by analysts. T
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Neurogene Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.